US4394448A
(en)
|
1978-02-24 |
1983-07-19 |
Szoka Jr Francis C |
Method of inserting DNA into living cells
|
DE3068743D1
(en)
|
1980-01-16 |
1984-08-30 |
Weder Hans G |
Process and dialysis-installation for the preparation of bilayer-vesicles and their use
|
US4598051A
(en)
|
1980-03-12 |
1986-07-01 |
The Regents Of The University Of California |
Liposome conjugates and diagnostic methods therewith
|
US4515736A
(en)
|
1983-05-12 |
1985-05-07 |
The Regents Of The University Of California |
Method for encapsulating materials into liposomes
|
US5208036A
(en)
|
1985-01-07 |
1993-05-04 |
Syntex (U.S.A.) Inc. |
N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
|
US4897355A
(en)
|
1985-01-07 |
1990-01-30 |
Syntex (U.S.A.) Inc. |
N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
|
US5545412A
(en)
|
1985-01-07 |
1996-08-13 |
Syntex (U.S.A.) Inc. |
N-[1, (1-1)-dialkyloxy]-and N-[1, (1-1)-dialkenyloxy]-alk-1-yl-n,n,n-tetrasubstituted ammonium lipids and uses therefor
|
US5320906A
(en)
|
1986-12-15 |
1994-06-14 |
Vestar, Inc. |
Delivery vehicles with amphiphile-associated active ingredient
|
JPH085107B2
(ja)
|
1988-08-04 |
1996-01-24 |
ファナック株式会社 |
電動式射出成形機における位置決め方式
|
IL91664A
(en)
|
1988-09-28 |
1993-05-13 |
Yissum Res Dev Co |
Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
|
US5703055A
(en)
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
FR2645866B1
(fr)
|
1989-04-17 |
1991-07-05 |
Centre Nat Rech Scient |
Nouvelles lipopolyamines, leur preparation et leur emploi
|
JPH03126211A
(ja)
|
1989-10-12 |
1991-05-29 |
Nippon Chemicon Corp |
電解コンデンサ用電解液
|
US5013556A
(en)
|
1989-10-20 |
1991-05-07 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
US5225212A
(en)
|
1989-10-20 |
1993-07-06 |
Liposome Technology, Inc. |
Microreservoir liposome composition and method
|
US5279833A
(en)
|
1990-04-04 |
1994-01-18 |
Yale University |
Liposomal transfection of nucleic acids into animal cells
|
US5264618A
(en)
|
1990-04-19 |
1993-11-23 |
Vical, Inc. |
Cationic lipids for intracellular delivery of biologically active molecules
|
US5283185A
(en)
|
1991-08-28 |
1994-02-01 |
University Of Tennessee Research Corporation |
Method for delivering nucleic acids into cells
|
US6001644A
(en)
|
1991-12-17 |
1999-12-14 |
The Regents Of The University Of California |
Mammalian transformation complex comprising a lipid carrier and DNA encoding CFTR
|
US5858784A
(en)
|
1991-12-17 |
1999-01-12 |
The Regents Of The University Of California |
Expression of cloned genes in the lung by aerosol- and liposome-based delivery
|
CA2130264A1
(en)
|
1992-02-19 |
1993-09-02 |
Harris Busch |
Oligonucleotide modulation of cell growth
|
WO1993025673A1
(en)
|
1992-06-04 |
1993-12-23 |
The Regents Of The University Of California |
In vivo gene therapy with intron-free sequence of interest
|
US5334761A
(en)
|
1992-08-28 |
1994-08-02 |
Life Technologies, Inc. |
Cationic lipids
|
WO1995002698A1
(en)
|
1993-07-12 |
1995-01-26 |
Life Technologies, Inc. |
Composition and methods for transfecting eukaryotic cells
|
US5674908A
(en)
|
1993-12-20 |
1997-10-07 |
Life Technologies, Inc. |
Highly packed polycationic ammonium, sulfonium and phosphonium lipids
|
FR2714830B1
(fr)
|
1994-01-10 |
1996-03-22 |
Rhone Poulenc Rorer Sa |
Composition contenant des acides nucléiques, préparation et utilisations.
|
US6989434B1
(en)
|
1994-02-11 |
2006-01-24 |
Invitrogen Corporation |
Reagents for intracellular delivery of macromolecules
|
US6075012A
(en)
|
1994-02-11 |
2000-06-13 |
Life Technologies, Inc. |
Reagents for intracellular delivery of macromolecules
|
CA2194221C
(en)
|
1994-06-22 |
2001-01-02 |
Timothy D. Heath |
Cationic amphiphiles
|
FR2722506B1
(fr)
|
1994-07-13 |
1996-08-14 |
Rhone Poulenc Rorer Sa |
Composition contenant des acides nucleiques, preparation et utilisations
|
US5753613A
(en)
|
1994-09-30 |
1998-05-19 |
Inex Pharmaceuticals Corporation |
Compositions for the introduction of polyanionic materials into cells
|
US5885613A
(en)
|
1994-09-30 |
1999-03-23 |
The University Of British Columbia |
Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
|
US5820873A
(en)
|
1994-09-30 |
1998-10-13 |
The University Of British Columbia |
Polyethylene glycol modified ceramide lipids and liposome uses thereof
|
US5627159A
(en)
|
1994-10-27 |
1997-05-06 |
Life Technologies, Inc. |
Enhancement of lipid cationic transfections in the presence of serum
|
US5800833A
(en)
|
1995-02-27 |
1998-09-01 |
University Of British Columbia |
Method for loading lipid vesicles
|
US5981501A
(en)
|
1995-06-07 |
1999-11-09 |
Inex Pharmaceuticals Corp. |
Methods for encapsulating plasmids in lipid bilayers
|
CA2223179A1
(en)
|
1995-06-07 |
1996-12-19 |
Bob Dale Brown |
Phosphonic acid-based cationic lipids
|
US20030069173A1
(en)
|
1998-03-16 |
2003-04-10 |
Life Technologies, Inc. |
Peptide-enhanced transfections
|
US5705385A
(en)
|
1995-06-07 |
1998-01-06 |
Inex Pharmaceuticals Corporation |
Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
|
EP0874910A4
(en)
|
1995-06-07 |
1999-04-21 |
Life Technologies Inc |
ENHANCED CATIONIC LIPID TRANSFECTION BY PEPTIDES
|
ES2231819T3
(es)
|
1995-06-07 |
2005-05-16 |
Inex Pharmaceuticals Corp |
Particulas de lipido-acido nucleico preparadas a traves de un intermedio complejo de lipido-acido nucleico hidrofobo y uso para transferir genes.
|
US6051429A
(en)
|
1995-06-07 |
2000-04-18 |
Life Technologies, Inc. |
Peptide-enhanced cationic lipid transfections
|
US5811406A
(en)
|
1995-06-07 |
1998-09-22 |
Regents Of The University Of California |
Dry powder formulations of polynucleotide complexes
|
CA2223088A1
(en)
|
1995-06-07 |
1996-12-19 |
Bob Dale Brown |
Novel carbamate-based cationic lipids
|
US7422902B1
(en)
|
1995-06-07 |
2008-09-09 |
The University Of British Columbia |
Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
|
US6339173B1
(en)
|
1996-07-22 |
2002-01-15 |
Promega Biosciences, Inc. |
Amide-based cationic lipids
|
US6020526A
(en)
|
1995-07-21 |
2000-02-01 |
Genta, Incorporated |
Amide-based cationic lipids
|
US6330349B1
(en)
|
1995-11-30 |
2001-12-11 |
Chromavision Medical Systems, Inc. |
Automated method for image analysis of residual protein
|
US5817856A
(en)
|
1995-12-11 |
1998-10-06 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Radiation-protective phospholipid and method
|
US6284267B1
(en)
|
1996-08-14 |
2001-09-04 |
Nutrimed Biotech |
Amphiphilic materials and liposome formulations thereof
|
US6110491A
(en)
|
1996-10-22 |
2000-08-29 |
Hermes Biosciences, Inc. |
Compound-loaded liposomes and methods for their preparation
|
US6210707B1
(en)
|
1996-11-12 |
2001-04-03 |
The Regents Of The University Of California |
Methods of forming protein-linked lipidic microparticles, and compositions thereof
|
US6034135A
(en)
|
1997-03-06 |
2000-03-07 |
Promega Biosciences, Inc. |
Dimeric cationic lipids
|
US5877220A
(en)
|
1997-03-06 |
1999-03-02 |
Genta, Incorporated |
Amide-based oligomeric cationic lipids
|
AU733310C
(en)
|
1997-05-14 |
2001-11-29 |
University Of British Columbia, The |
High efficiency encapsulation of charged therapeutic agents in lipid vesicles
|
WO1998051285A2
(en)
|
1997-05-15 |
1998-11-19 |
Genzyme Corporation |
Cationic amphiphile formulations
|
CA2792406A1
(en)
|
1997-10-10 |
1999-04-22 |
Tekmira Pharmaceuticals Corporation |
Methods for encapsulating nucleic acids in lipid bilayers
|
US6410328B1
(en)
|
1998-02-03 |
2002-06-25 |
Protiva Biotherapeutics Inc. |
Sensitizing cells to compounds using lipid-mediated gene and compound delivery
|
CA2271582A1
(en)
|
1998-05-14 |
1999-11-14 |
Sean C. Semple |
Method for administration of therapeutic agents, including antisense, with repeat dosing
|
DE69906977T2
(de)
|
1998-07-20 |
2004-05-19 |
Protiva Biotherapeutics Inc., Burnaby |
In liposomen verkapselte nukleinsäurekomplexe
|
US6900049B2
(en)
|
1998-09-10 |
2005-05-31 |
Cell Genesys, Inc. |
Adenovirus vectors containing cell status-specific response elements and methods of use thereof
|
EP1829856A3
(en)
|
1998-11-12 |
2009-02-25 |
Invitrogen Corporation |
Transfection reagents
|
US6649780B1
(en)
|
1998-12-22 |
2003-11-18 |
Valentis, Inc. |
Cationic lipids
|
CA2370690A1
(en)
|
1999-04-20 |
2000-10-26 |
The University Of British Columbia |
Cationic peg-lipids and methods of use
|
US6696424B1
(en)
|
1999-05-28 |
2004-02-24 |
Vical Incorporated |
Cytofectin dimers and methods of use thereof
|
US20010048940A1
(en)
|
1999-06-18 |
2001-12-06 |
Jennifer D. Tousignant |
Cationic amphiphile micellar complexes
|
KR100758158B1
(ko)
|
1999-07-14 |
2007-09-12 |
알자 코포레이션 |
중성 지질중합체 및 그를 함유하는 리포솜 조성물
|
DE60017406T2
(de)
|
1999-07-15 |
2005-09-29 |
Inex Pharmaceuticals Corp., Burnaby |
Verfahren zur herstellung von in lipid verkapselten therapeutischen wirkstoffen
|
WO2001051003A2
(en)
|
2000-01-10 |
2001-07-19 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Use of lipid conjugates in the treatment of disease
|
WO2002081628A2
(en)
|
2001-04-05 |
2002-10-17 |
Ribozyme Pharmaceuticals, Incorporated |
Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies
|
US6622305B1
(en)
|
2000-02-25 |
2003-09-16 |
Opentv, Inc. |
System and method for displaying near video on demand
|
EP2345742B1
(en)
|
2000-03-30 |
2014-06-11 |
The Whitehead Institute for Biomedical Research |
RNA sequence-specific mediators of RNA interference
|
CN1254234C
(zh)
|
2000-06-09 |
2006-05-03 |
莱古伦公司 |
质粒dna(lipogenestm)和含细胞核定位信号/促融合肽缀合物的治疗剂包封到定向脂质体复合体中
|
US20030072794A1
(en)
|
2000-06-09 |
2003-04-17 |
Teni Boulikas |
Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes
|
AU2001287114A1
(en)
|
2000-09-06 |
2002-03-22 |
Neurogen Corporation |
Aryl substituted tetrahydroindazoles and their use as ligands for the gaba-a receptor
|
WO2002034236A2
(en)
|
2000-10-25 |
2002-05-02 |
The University Of British Columbia |
Lipid formulations for target delivery
|
CA2427068A1
(en)
|
2000-10-27 |
2002-05-02 |
Invitrogen Corporation |
Method for introducing antisense oligonucleotides into eucaryotic cells
|
JP5355838B2
(ja)
|
2000-11-20 |
2013-11-27 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
キラルな光異性化可能な化合物
|
ES2728168T3
(es)
|
2000-12-01 |
2019-10-22 |
Max Planck Gesellschaft |
Moléculas pequeñas de ARN que median en la interferencia de ARN
|
WO2002087541A1
(en)
|
2001-04-30 |
2002-11-07 |
Protiva Biotherapeutics Inc. |
Lipid-based formulations for gene transfer
|
US20040142892A1
(en)
|
2001-04-30 |
2004-07-22 |
The University Of British Columbia |
Autogene nucleic acids encoding a secretable RNA polymerase
|
DE60237162D1
(de)
|
2001-10-03 |
2010-09-09 |
Celator Pharmaceuticals Inc |
Liposomenladung mit metallionen
|
US20040063654A1
(en)
|
2001-11-02 |
2004-04-01 |
Davis Mark E. |
Methods and compositions for therapeutic use of RNA interference
|
US7074596B2
(en)
|
2002-03-25 |
2006-07-11 |
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Synthesis and use of anti-reverse mRNA cap analogues
|
EP1509203B1
(en)
|
2002-05-15 |
2016-04-13 |
California Pacific Medical Center |
Delivery of nucleic acid-like compounds
|
DK1519714T3
(da)
|
2002-06-28 |
2011-01-31 |
Protiva Biotherapeutics Inc |
Fremgangsmåde og apparat til fremstilling af liposomer
|
DE10250870A1
(de)
|
2002-10-31 |
2004-05-13 |
Switch Biotech Ag |
Zusammensetzung enthaltend Aktivatoren von IK-Kaliumkanälen und Calcineurin-Antagonisten und deren Verwendung
|
US20040146941A1
(en)
|
2002-11-04 |
2004-07-29 |
Biliang Zhang |
Chemical encoding technology for combinatorial synthesis
|
ATE477337T1
(de)
|
2003-01-16 |
2010-08-15 |
Univ Pennsylvania |
Zusammensetzungen und verfahren zur sirna-hemmung von icam-1
|
WO2004072069A1
(en)
|
2003-02-14 |
2004-08-26 |
Glaxo Group Limited |
Carboxamide derivatives
|
US7803781B2
(en)
|
2003-02-28 |
2010-09-28 |
Isis Pharmaceuticals, Inc. |
Modulation of growth hormone receptor expression and insulin-like growth factor expression
|
DE10314976A1
(de)
|
2003-04-02 |
2004-10-14 |
Bayer Healthcare Ag |
Verbesserte Penetration von Wirkstoffen in Zellen und Organe
|
DE10327871A1
(de)
|
2003-06-18 |
2005-01-05 |
Goldschmidt Ag |
Verwendung von Alkylguanidin-Verbindungen zur Behandlung und Nachbehandlung von Haaren
|
JP4695075B2
(ja)
|
2003-06-18 |
2011-06-08 |
イッスム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム |
トランスフェクションで使用するためのスフィンゴ脂質ポリアルキルアミン抱合体
|
EP1493423B1
(de)
|
2003-06-18 |
2006-06-14 |
Goldschmidt GmbH |
Haarbehandlungsmittel und Haarnachbehandlungsmittel zum Schutz vor Schäden durch chemische Behandlung und zur Reparatur bereits geschädigter Haare enthaltend als Wirksubstanz Alkylguanidin-Verbindungen
|
US20050000030A1
(en)
|
2003-06-27 |
2005-01-06 |
Dupont Jeffrey Scott |
Fabric care compositions for lipophilic fluid systems
|
NZ544637A
(en)
|
2003-07-16 |
2010-04-30 |
Protiva Biotherapeutics Inc |
Lipid encapsulated interfering RNA
|
EP1664316B1
(en)
|
2003-09-15 |
2012-08-29 |
Protiva Biotherapeutics Inc. |
Polyethyleneglycol-modified lipid compounds and uses thereof
|
EP1547581A1
(en)
|
2003-12-23 |
2005-06-29 |
Vectron Therapeutics AG |
Liposomal vaccine for the treatment of human hematological malignancies
|
JP4483300B2
(ja)
|
2004-01-15 |
2010-06-16 |
セイコーエプソン株式会社 |
光走査装置および画像形成装置
|
US7470713B2
(en)
|
2004-02-23 |
2008-12-30 |
Bristol-Myers Squibb Company |
Imidazole based kinase inhibitors
|
WO2005107712A1
(en)
|
2004-05-03 |
2005-11-17 |
Hermes Biosciences, Inc. |
Liposomes useful for drug delivery
|
CN103356636A
(zh)
|
2004-05-23 |
2013-10-23 |
杰勒德·M·豪斯 |
Theramutein调节剂
|
EP1781593B1
(en)
|
2004-06-07 |
2011-12-14 |
Protiva Biotherapeutics Inc. |
Cationic lipids and methods of use
|
ATE536418T1
(de)
|
2004-06-07 |
2011-12-15 |
Protiva Biotherapeutics Inc |
Lipidverkapselte interferenz-rna
|
CA2572439A1
(en)
|
2004-07-02 |
2006-01-12 |
Protiva Biotherapeutics, Inc. |
Immunostimulatory sirna molecules and uses therefor
|
US7749520B2
(en)
*
|
2004-07-07 |
2010-07-06 |
Statens Serum Institut |
Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids
|
CN101072588B
(zh)
|
2004-10-06 |
2012-11-28 |
不列颠哥伦比亚抗癌机构 |
用于治疗癌症的具有改善的药物保留的脂质体
|
WO2006053430A1
(en)
|
2004-11-17 |
2006-05-26 |
Protiva Biotherapeutics, Inc. |
Sirna silencing of apolipoprotein b
|
WO2006102163A2
(en)
|
2005-03-17 |
2006-09-28 |
Invitrogen Corporation |
Transfection reagents for non-adherent suspension cells
|
US8188128B2
(en)
|
2005-05-12 |
2012-05-29 |
The University Of Medicine And Dentistry Of New Jersey |
Opioid receptor subtype-selective agents
|
WO2007015877A2
(en)
|
2005-07-20 |
2007-02-08 |
Kalypsys, Inc. |
Inhibitors of p38 kinase and methods of treating inflammatory disorders
|
US9005654B2
(en)
|
2005-07-27 |
2015-04-14 |
Protiva Biotherapeutics, Inc. |
Systems and methods for manufacturing liposomes
|
LT2578685T
(lt)
|
2005-08-23 |
2019-06-10 |
The Trustees Of The University Of Pennsylvania |
Rnr, apimančios modifikuotus nukleozidus ir jų panaudojimo būdai
|
DE102005046490A1
(de)
|
2005-09-28 |
2007-03-29 |
Johannes-Gutenberg-Universität Mainz |
Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
|
US7838658B2
(en)
|
2005-10-20 |
2010-11-23 |
Ian Maclachlan |
siRNA silencing of filovirus gene expression
|
JP2006080560A
(ja)
|
2005-10-31 |
2006-03-23 |
Kansai Electric Power Co Inc:The |
光結合パワー半導体素子
|
CA2628300C
(en)
|
2005-11-02 |
2018-04-17 |
Protiva Biotherapeutics, Inc. |
Modified sirna molecules and uses thereof
|
US20070218122A1
(en)
|
2005-11-18 |
2007-09-20 |
Protiva Biotherapeutics, Inc. |
siRNA silencing of influenza virus gene expression
|
ES2439456T3
(es)
|
2005-12-08 |
2014-01-23 |
Hybrigenics S.A. |
Inhibidores de cisteína proteasas, las composiciones farmacéuticas de las mismas y sus aplicaciones terapéuticas
|
US7462615B2
(en)
|
2005-12-08 |
2008-12-09 |
Hybrigenics Sa |
Inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications
|
PE20071025A1
(es)
|
2006-01-31 |
2007-10-17 |
Mitsubishi Tanabe Pharma Corp |
Compuesto amina trisustituido
|
UY30244A1
(es)
|
2006-03-30 |
2007-11-30 |
Tanabe Seiyaku Co |
Un proceso para preparar derivados de tetrahidroquinolina
|
US8598333B2
(en)
|
2006-05-26 |
2013-12-03 |
Alnylam Pharmaceuticals, Inc. |
SiRNA silencing of genes expressed in cancer
|
EP2104671A2
(en)
|
2006-09-25 |
2009-09-30 |
Mutabilis SA |
Substituted heterocyclylcarbonylamino-acetic-acid-derivatives as inhibitors of bacterial heptose synthesis, methods for their preparation and biological applications of said inhibitors
|
WO2008064318A2
(en)
|
2006-11-22 |
2008-05-29 |
University Of Medicine And Dentistry Of New Jersey |
Peripheral opioid receptor active compounds
|
WO2008064317A1
(en)
|
2006-11-22 |
2008-05-29 |
University Of Medicine And Dentistry Of New Jersey |
Lipophilic opioid receptor active compounds
|
WO2008091681A2
(en)
|
2007-01-23 |
2008-07-31 |
Housey Gerard M |
Theramutein modulators
|
WO2008101029A2
(en)
|
2007-02-13 |
2008-08-21 |
Xenon Pharmaceuticals Inc. |
Use of thiazole, oxazole and imidazole compounds for the treatment of sodium channel-mediated diseases or conditions
|
PE20081785A1
(es)
|
2007-02-19 |
2009-01-12 |
Novartis Ag |
Derivados de ciclohexil-amida del acido aril carboxilico
|
CA2683444A1
(en)
|
2007-04-13 |
2008-10-23 |
Ptc Therapeutics, Inc. |
Administration of carboline derivatives useful in the treatment of cancer and other diseases
|
JP4834699B2
(ja)
|
2007-07-30 |
2011-12-14 |
田辺三菱製薬株式会社 |
医薬組成物
|
JP4846769B2
(ja)
|
2007-07-30 |
2011-12-28 |
田辺三菱製薬株式会社 |
医薬組成物
|
DE102007038957A1
(de)
|
2007-08-17 |
2009-02-19 |
Merck Patent Gmbh |
6-Thioxo-pyridazinderivate
|
TWI649303B
(zh)
|
2007-08-17 |
2019-02-01 |
杜邦股份有限公司 |
製備4-乙醯基-n-〔2-側氧基-2-〔(2,2,2-三氟乙基)胺基〕乙基〕-1-萘甲醯胺之化合物及方法
|
WO2009082817A1
(en)
|
2007-12-27 |
2009-07-09 |
Protiva Biotherapeutics, Inc. |
Silencing of polo-like kinase expression using interfering rna
|
WO2009086558A1
(en)
|
2008-01-02 |
2009-07-09 |
Tekmira Pharmaceuticals Corporation |
Improved compositions and methods for the delivery of nucleic acids
|
JP2011512536A
(ja)
|
2008-02-15 |
2011-04-21 |
シグマ−アルドリッチ・カンパニー |
ジカチオン液体塩およびその使用方法
|
CA2716514A1
(en)
|
2008-02-21 |
2009-08-27 |
Sequoia Pharmaceuticals, Inc. |
Hiv protease inhibitor and cytochrome p450 inhibitor combinations
|
AU2009221775B2
(en)
|
2008-03-05 |
2015-05-07 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of Eg5 and VEGF genes
|
WO2009114763A2
(en)
|
2008-03-13 |
2009-09-17 |
Perkinelmer Las, Inc. |
Enzymatic substrates for multiple detection systems
|
EP2281041B1
(en)
|
2008-04-15 |
2014-07-02 |
Protiva Biotherapeutics Inc. |
Silencing of csn5 gene expression using interfering rna
|
PL2279254T3
(pl)
|
2008-04-15 |
2017-11-30 |
Protiva Biotherapeutics Inc. |
Nowe preparaty lipidowe do dostarczania kwasów nukleinowych
|
WO2009132131A1
(en)
|
2008-04-22 |
2009-10-29 |
Alnylam Pharmaceuticals, Inc. |
Amino lipid based improved lipid formulation
|
ES2331282B1
(es)
|
2008-06-25 |
2010-10-21 |
Consejo Superior De Investigaciones Cientificas (Csic) (45%) |
Hidrazidas de sistemas heterociclicos y su uso en el tratamiento de enfermedades neurodegenerativas.
|
EP2313091A4
(en)
|
2008-07-14 |
2012-04-04 |
Univ Kingston |
PHARMACEUTICAL COMPOSITIONS WITH RET-HEMMERN AND METHOD FOR THE TREATMENT OF CANCER
|
EP2350043B9
(en)
|
2008-10-09 |
2014-08-20 |
TEKMIRA Pharmaceuticals Corporation |
Improved amino lipids and methods for the delivery of nucleic acids
|
ES2656516T3
(es)
|
2008-10-20 |
2018-02-27 |
Alnylam Pharmaceuticals, Inc. |
Composiciones y métodos para inhibir la expresión de transtiretina
|
WO2010048536A2
(en)
|
2008-10-23 |
2010-04-29 |
Alnylam Pharmaceuticals, Inc. |
Processes for preparing lipids
|
KR102264822B1
(ko)
|
2008-11-10 |
2021-06-14 |
알닐람 파마슈티칼스 인코포레이티드 |
치료제 운반용 신규 지질 및 조성물
|
JP5212350B2
(ja)
|
2008-12-24 |
2013-06-19 |
住友化学株式会社 |
含ハロゲン有機硫黄化合物およびその用途
|
US20120101148A1
(en)
|
2009-01-29 |
2012-04-26 |
Alnylam Pharmaceuticals, Inc. |
lipid formulation
|
DE102009000641A1
(de)
|
2009-02-05 |
2010-08-12 |
Evonik Goldschmidt Gmbh |
Verfahren zur Herstellung von antistatisch angerüsteten Kunststeinen für Flächengebilde
|
CN102421900B
(zh)
|
2009-03-12 |
2015-07-22 |
阿尔尼拉姆医药品有限公司 |
用于抑制Eg5和VEGF基因表达的脂质配制的组合物以及方法
|
CA3042927C
(en)
|
2009-05-05 |
2022-05-17 |
Arbutus Biopharma Corporation |
Lipid compositions for the delivery of therapeutic agents
|
US20120157401A1
(en)
|
2009-05-27 |
2012-06-21 |
Ptc Therapeutics, Inc. |
Methods for treating neurofibromatosis
|
ES2826950T3
(es)
|
2009-05-27 |
2021-05-19 |
Ptc Therapeutics Inc |
Métodos para tratar cáncer y afecciones no neoplásicas
|
WO2010138652A1
(en)
|
2009-05-27 |
2010-12-02 |
Ptc Therapeutics, Inc. |
Methods for treating kaposi sarcoma
|
US8703726B2
(en)
|
2009-05-27 |
2014-04-22 |
Ptc Therapeutics, Inc. |
Methods for treating prostate conditions
|
WO2010138659A1
(en)
|
2009-05-27 |
2010-12-02 |
Ptc Therapeutics, Inc. |
Methods for treating brain tumors
|
US20120202801A1
(en)
|
2009-05-27 |
2012-08-09 |
Liangxian Cao |
Methods for treating breast cancer
|
PT2437753T
(pt)
|
2009-06-05 |
2016-11-23 |
Infectious Disease Res Inst |
Adjuvantes lipídicos de glucopiranosilo sintéticos e composições de vacina contendo os mesmos
|
WO2010148422A1
(en)
|
2009-06-25 |
2010-12-29 |
Walter And Eliza Hall Institute Of Medical Research |
Compounds and methods for treating parasitic infestations
|
WO2011000108A1
(en)
|
2009-07-01 |
2011-01-06 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing apolipoprotein b
|
JP5766188B2
(ja)
|
2009-07-01 |
2015-08-19 |
プロチバ バイオセラピューティクス インコーポレイティッド |
固形腫瘍に治療剤を送達するための脂質製剤
|
WO2011000106A1
(en)
|
2009-07-01 |
2011-01-06 |
Protiva Biotherapeutics, Inc. |
Improved cationic lipids and methods for the delivery of therapeutic agents
|
US8716464B2
(en)
|
2009-07-20 |
2014-05-06 |
Thomas W. Geisbert |
Compositions and methods for silencing Ebola virus gene expression
|
WO2011017548A1
(en)
|
2009-08-05 |
2011-02-10 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
|
WO2011021218A2
(en)
|
2009-08-12 |
2011-02-24 |
Msn Laboratories Limited |
Process for the preparation of 4-[3,5-bis(2-hydroxyphenyl)-1h-1,2,4-triazol-1-yl]-benzoic acid and its amine salts
|
EP2501696B1
(en)
|
2009-10-15 |
2016-12-28 |
Guerbet |
Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
|
CA2816925C
(en)
|
2009-11-04 |
2023-01-10 |
The University Of British Columbia |
Nucleic acid-containing lipid particles and related methods
|
EP2506879A4
(en)
|
2009-12-01 |
2014-03-19 |
Protiva Biotherapeutics Inc |
PREPARATIONS OF SNALP CONTAINING ANTIOXIDANTS
|
AU2010330814B2
(en)
|
2009-12-18 |
2017-01-12 |
Acuitas Therapeutics Inc. |
Methods and compositions for delivery of nucleic acids
|
EP2515914A4
(en)
|
2009-12-23 |
2013-09-11 |
Scripps Research Inst |
BIOCONJUGATION OF TYROSINE BY EYE REACTIONS IN AQUEOUS MEDIA
|
CN102883602B
(zh)
|
2010-02-16 |
2017-07-18 |
Uwm研究基金会有限公司 |
降低细菌的毒力的方法
|
US8455455B1
(en)
|
2010-03-31 |
2013-06-04 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing genes involved in hemorrhagic fever
|
EP2569276B1
(en)
|
2010-05-12 |
2021-02-24 |
Arbutus Biopharma Corporation |
Novel cationic lipids and methods of use thereof
|
US9006417B2
(en)
|
2010-06-30 |
2015-04-14 |
Protiva Biotherapeutics, Inc. |
Non-liposomal systems for nucleic acid delivery
|
HUE058896T2
(hu)
|
2010-10-01 |
2022-09-28 |
Modernatx Inc |
N1-metil-pszeudo-uracilt tartalmazó ribonukleinsavak és azok felhasználásai
|
WO2012068176A1
(en)
|
2010-11-15 |
2012-05-24 |
Life Technologies Corporation |
Amine-containing transfection reagents and methods for making and using same
|
EP3988537A1
(en)
|
2011-12-07 |
2022-04-27 |
Alnylam Pharmaceuticals, Inc. |
Biodegradable lipids for the delivery of active agents
|
US10155031B2
(en)
|
2012-11-28 |
2018-12-18 |
Biontech Rna Pharmaceuticals Gmbh |
Individualized vaccines for cancer
|
AU2013355258A1
(en)
|
2012-12-07 |
2015-06-11 |
Alnylam Pharmaceuticals, Inc. |
Improved nucleic acid lipid particle formulations
|
EP3556353A3
(en)
|
2014-02-25 |
2020-03-18 |
Merck Sharp & Dohme Corp. |
Lipid nanoparticle vaccine adjuvants and antigen delivery systems
|
EP3041948B1
(en)
|
2014-11-10 |
2019-01-09 |
Modernatx, Inc. |
Alternative nucleic acid molecules containing reduced uracil content and uses thereof
|
CN114642735A
(zh)
|
2015-01-21 |
2022-06-21 |
菲泽尔克斯公司 |
用于将治疗剂和诊断剂递送到细胞中的方法、组合物和***
|
EP3289083A4
(en)
|
2015-04-27 |
2018-12-19 |
The Trustees Of The University Of Pennsylvania |
Nucleoside-modified rna for inducing an adaptive immune response
|
DK3313829T3
(da)
|
2015-06-29 |
2024-06-17 |
Acuitas Therapeutics Inc |
Lipider og lipide nanopartikelformuleringer til levering af nukleinsyrer
|
EP3364950A4
(en)
|
2015-10-22 |
2019-10-23 |
ModernaTX, Inc. |
VACCINES AGAINST TROPICAL DISEASES
|
AU2016366978B2
(en)
|
2015-12-10 |
2022-07-28 |
Modernatx, Inc. |
Compositions and methods for delivery of therapeutic agents
|
US20180369143A1
(en)
|
2015-12-15 |
2018-12-27 |
British Columbia Cancer Agency Branch |
Metal complexed therapeutic agents and lipid-based nanoparticulate formulations thereof
|
AU2016377681B2
(en)
|
2015-12-22 |
2021-05-13 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of agents
|
WO2017173054A1
(en)
|
2016-03-30 |
2017-10-05 |
Intellia Therapeutics, Inc. |
Lipid nanoparticle formulations for crispr/cas components
|
JP2019525901A
(ja)
|
2016-06-14 |
2019-09-12 |
モデルナティエックス インコーポレイテッドModernaTX,Inc. |
脂質ナノ粒子の安定化製剤
|
EP3519578B1
(en)
|
2016-10-03 |
2021-12-22 |
Precision Nanosystems Inc |
Compositions for transfecting resistant cell types
|
WO2018119514A1
(en)
|
2016-12-28 |
2018-07-05 |
Precision Nanosystems Inc. |
Compositions for transfecting resistant cell types
|
US20190314486A1
(en)
|
2016-10-21 |
2019-10-17 |
Merck Sharp & Dohme Corp. |
Influenza hemagglutinin protein vaccines
|
EP3532103A1
(en)
|
2016-10-26 |
2019-09-04 |
Acuitas Therapeutics, Inc. |
Lipid nanoparticle formulations
|
EP3532094A1
(en)
|
2016-10-26 |
2019-09-04 |
CureVac AG |
Lipid nanoparticle mrna vaccines
|
EP3532097A1
(en)
|
2016-10-27 |
2019-09-04 |
The Trustees Of The University Of Pennsylvania |
Nucleoside-modified rna for inducing an adaptive immune response
|
WO2018089540A1
(en)
|
2016-11-08 |
2018-05-17 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
US10526284B2
(en)
|
2016-12-21 |
2020-01-07 |
Arcturus Therapeutics, Inc. |
Ionizable cationic lipid for RNA delivery
|
EP3562510A4
(en)
|
2016-12-30 |
2021-01-06 |
Genevant Sciences GmbH |
BRANCHED PEG MOLECULES AND ASSOCIATED COMPOSITIONS AND PROCEDURES
|
CA3055653A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Lipid nanoparticle formulation
|
RS63953B1
(sr)
|
2017-03-15 |
2023-02-28 |
Modernatx Inc |
Jedinjenje i kompozicije za intracelularnu isporuku terapeutskih sredstava
|
WO2018200613A1
(en)
|
2017-04-26 |
2018-11-01 |
Merck Sharp & Dohme Corp. |
Hsv antigenic peptides and hsv protein vaccines
|
AU2018266705B2
(en)
|
2017-05-08 |
2023-05-04 |
Gritstone Bio, Inc. |
Alphavirus neoantigen vectors
|
EP4253544A3
(en)
|
2017-05-18 |
2023-12-20 |
ModernaTX, Inc. |
Modified messenger rna comprising functional rna elements
|
US20210198200A1
(en)
|
2017-06-14 |
2021-07-01 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of agents
|
US11786607B2
(en)
|
2017-06-15 |
2023-10-17 |
Modernatx, Inc. |
RNA formulations
|
US20200254086A1
(en)
|
2017-08-18 |
2020-08-13 |
Moderna TX, Inc. |
Efficacious mrna vaccines
|
AU2018326799A1
(en)
|
2017-08-31 |
2020-02-27 |
Modernatx, Inc. |
Methods of making lipid nanoparticles
|
EP3679148A4
(en)
|
2017-09-08 |
2021-06-09 |
Generation Bio Co. |
LIPID NANOPARTICLE FORMULATIONS OF NON-VIRAL CAPSIDE-FREE DNA VECTORS
|
TWI833708B
(zh)
|
2017-09-29 |
2024-03-01 |
美商英特利亞醫療公司 |
調配物
|
WO2019089828A1
(en)
|
2017-10-31 |
2019-05-09 |
Acuitas Therapeutics, Inc. |
Lamellar lipid nanoparticles
|
AU2018392716A1
(en)
|
2017-12-20 |
2020-06-18 |
Translate Bio, Inc. |
Improved composition and methods for treatment of ornithine transcarbamylase deficiency
|
EP3740241A1
(en)
|
2018-01-18 |
2020-11-25 |
eTheRNA Immunotherapies NV |
Lipid nanoparticles
|
CA3088546A1
(en)
|
2018-01-29 |
2019-08-01 |
Merck Sharp & Dohme Corp. |
Stabilized rsv f proteins and uses thereof
|
WO2019200171A1
(en)
|
2018-04-11 |
2019-10-17 |
Modernatx, Inc. |
Messenger rna comprising functional rna elements
|
CN112292395A
(zh)
|
2018-04-17 |
2021-01-29 |
库瑞瓦格股份公司 |
用于疫苗接种的新型rsv rna分子和组合物
|
EP3787688A4
(en)
|
2018-04-29 |
2021-11-17 |
Precision Nanosystems Inc |
COMPOSITIONS FOR TRANSFECTION OF RESISTANT CELL TYPES
|
US20210315820A1
(en)
|
2018-07-30 |
2021-10-14 |
Trucode Gene Repair, Inc. |
Lipid nanoparticle formulations comprising nucleic acid mimics
|
JP2022501336A
(ja)
|
2018-09-14 |
2022-01-06 |
モダーナティエックス・インコーポレイテッドModernaTX, Inc. |
mRNA治療薬を使用したがんを治療するための方法及び組成物
|
JP7410135B2
(ja)
|
2018-09-19 |
2024-01-09 |
モデルナティエックス インコーポレイテッド |
治療薬の細胞内送達のための化合物及び組成物
|
JP2022501348A
(ja)
|
2018-09-19 |
2022-01-06 |
モデルナティエックス インコーポレイテッドModernaTX, Inc. |
ステロール類似体及びその使用
|
US20210378980A1
(en)
|
2018-09-20 |
2021-12-09 |
Modernatx, Inc. |
Preparation of lipid nanoparticles and methods of administration thereof
|
MA53734A
(fr)
|
2018-09-27 |
2021-08-04 |
Modernatx Inc |
Polynucléotides codant pour l'arginase 1 pour le traitement d'une déficience en arginase
|
WO2020070040A1
(en)
|
2018-10-01 |
2020-04-09 |
Johannes Gutenberg-Universität Mainz |
Rna particles comprising polysarcosine
|
WO2020069718A1
(en)
|
2018-10-01 |
2020-04-09 |
Johannes Gutenberg-Universität Mainz |
Rna particles comprising polysarcosine
|
RS65449B1
(sr)
|
2018-10-09 |
2024-05-31 |
The Univ Of British Columbia |
Supstance i sistemi koji obuhvataju vezikule kompetentne za transfekciju bez organskih rastvarača i deterdženata i metode za to
|
TW202039534A
(zh)
|
2018-12-14 |
2020-11-01 |
美商美國禮來大藥廠 |
KRAS變體mRNA分子
|
CN113939282A
(zh)
|
2019-01-31 |
2022-01-14 |
摩登纳特斯有限公司 |
制备脂质纳米颗粒的方法
|
AU2020241756A1
(en)
|
2019-03-19 |
2021-11-04 |
Arcturus Therapeutics, Inc. |
Method of making lipid-encapsulated RNA nanoparticles
|
WO2020198697A1
(en)
|
2019-03-28 |
2020-10-01 |
Intellia Therapeutics, Inc. |
Compositions and methods comprising a ttr guide rna and a polynucleotide encoding an rna-guided dna binding agent
|
KR20220004984A
(ko)
|
2019-03-28 |
2022-01-12 |
인텔리아 테라퓨틱스, 인크. |
Ttr 유전자 편집을 위한 조성물 및 방법 및 코르티코스테로이드를 포함하는 attr 아밀로이드증의 치료 또는 그의 용도
|
KR20220022050A
(ko)
|
2019-03-29 |
2022-02-23 |
바이오엔테크 유에스 인크. |
지속적인 임상 이익을 위한 암 바이오마커
|
WO2020200472A1
(en)
|
2019-04-05 |
2020-10-08 |
Biontech Rna Pharmaceuticals Gmbh |
Preparation and storage of liposomal rna formulations suitable for therapy
|
CA3133394A1
(en)
|
2019-04-15 |
2020-10-22 |
Precision Nanosystems Inc. |
Nonviral modification of t cell gene expression
|
WO2020219941A1
(en)
|
2019-04-26 |
2020-10-29 |
Genevant Sciences Gmbh |
Lipid nanoparticles
|
MA55896A
(fr)
|
2019-05-07 |
2022-03-16 |
Modernatx Inc |
Polynucléotides servant à perturber l'activité de cellule immunitaire et procédés pour les utiliser
|
DK3986866T3
(da)
|
2019-06-20 |
2024-03-04 |
Prec Nanosystems Ulc |
Ioniserbare lipider til nukleinsyrelevering
|
MA56517A
(fr)
|
2019-06-24 |
2022-04-27 |
Modernatx Inc |
Arn messager comprenant des éléments d'arn fonctionnels et leurs utilisations
|
CA3143578A1
(en)
|
2019-06-29 |
2021-01-07 |
Precision Nanosystems Inc. |
Ionizable lipids for nucleic acid delivery
|
WO2021016430A1
(en)
|
2019-07-23 |
2021-01-28 |
Translate Bio, Inc. |
Stable compositions of mrna-loaded lipid nanoparticles and processes of making
|
AU2020319876A1
(en)
|
2019-07-31 |
2022-02-24 |
Modernatx, Inc. |
Compositions and methods for delivery of RNA interference agents to immune cells
|
CA3150061A1
(en)
|
2019-08-07 |
2021-02-11 |
Modernatx, Inc. |
Compositions and methods for enhanced delivery of agents
|
DE112020003843T5
(de)
|
2019-08-14 |
2022-05-19 |
Acuitas Therapeutics, Inc. |
Verbesserte Lipid-Nanopartikel zur Zuführung von Nukleinsäuren
|
EP4025196A4
(en)
|
2019-09-06 |
2023-07-12 |
Generation Bio Co. |
LIPID-NANOPARTICLE COMPOSITIONS WITH CLOSED-END DNA AND CLEAVABLE LIPIDS AND METHODS OF USE
|
WO2021050986A1
(en)
|
2019-09-11 |
2021-03-18 |
Modernatx, Inc. |
Lnp-formulated mrna therapeutics and use thereof for treating human subjects
|
CA3154618A1
(en)
|
2019-09-19 |
2021-03-25 |
Modernatx, Inc. |
Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
|
BR112022004771A2
(pt)
|
2019-09-19 |
2022-06-21 |
Modernatx Inc |
Compostos e composições de lipídio de grupo de cabeça para entrega intracelular de agentes terapêuticos
|
CA3155015A1
(en)
|
2019-09-19 |
2021-03-25 |
Modernatx, Inc. |
Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents
|
JP2022552371A
(ja)
|
2019-10-15 |
2022-12-15 |
モデルナティエックス インコーポレイテッド |
免疫調節ポリペプチドをコードするmRNA及びその使用
|
AU2020366519A1
(en)
|
2019-10-18 |
2022-05-26 |
The Trustees Of The University Of Pennsylvania |
Lipid nanoparticles and formulations thereof for CAR mRNA delivery
|
KR20220084365A
(ko)
|
2019-10-18 |
2022-06-21 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
약물 전달을 위한 지질 및 지질 나노입자 제형
|
US20220370357A1
(en)
|
2019-11-22 |
2022-11-24 |
Generation Bio Co. |
Ionizable lipids and nanoparticle compositions thereof
|
AU2020407285A1
(en)
|
2019-12-20 |
2022-08-11 |
CureVac SE |
Lipid nanoparticles for delivery of nucleic acids
|
WO2021142336A1
(en)
|
2020-01-08 |
2021-07-15 |
Puretech Lyt, Inc. |
Vesicle compositions for oral delivery
|
KR20230002300A
(ko)
|
2020-01-21 |
2023-01-05 |
이더알엔에이 이뮤노테라피스 엔브이 |
지질 나노입자
|
WO2021155274A1
(en)
|
2020-01-31 |
2021-08-05 |
Modernatx, Inc. |
Methods of preparing lipid nanoparticles
|
BR112022014627A2
(pt)
|
2020-02-04 |
2022-09-27 |
Curevac Ag |
Vacina contra coronavírus
|
WO2021178510A1
(en)
|
2020-03-03 |
2021-09-10 |
Arcturus Therapeutics, Inc. |
Compositions and methods for the treatment of ornithine transcarbamylase deficiency
|
WO2021178725A1
(en)
|
2020-03-04 |
2021-09-10 |
Verve Therapeutics, Inc. |
Compositions and methods for targeted rna delivery
|
CA3171219A1
(en)
|
2020-03-09 |
2021-09-16 |
Arcturus Therapeutics, Inc. |
Compositions and methods for inducing immune responses
|
JP2023519245A
(ja)
|
2020-03-25 |
2023-05-10 |
バイオエヌテック エスエー |
ポリサルコシンを含むrna粒子
|
WO2021195529A2
(en)
|
2020-03-27 |
2021-09-30 |
Generation Bio Co. |
Novel lipids and nanoparticle compositions thereof
|
IL296781A
(en)
|
2020-03-30 |
2022-11-01 |
BioNTech SE |
RNA compositions targeting claudin-18.2
|
IL297129A
(en)
|
2020-04-06 |
2022-12-01 |
Tiba Biotech Llc |
leading to efficient application of nucleic acids
|
IL297194A
(en)
|
2020-04-09 |
2022-12-01 |
Verve Therapeutics Inc |
Editing bases of angptl3 and methods of using it to treat diseases
|
WO2021213924A1
(en)
|
2020-04-22 |
2021-10-28 |
BioNTech SE |
Coronavirus vaccine
|
WO2021222287A2
(en)
|
2020-04-28 |
2021-11-04 |
Intellia Therapeutics, Inc. |
Methods of in vitro cell delivery
|
WO2021222801A2
(en)
|
2020-05-01 |
2021-11-04 |
Arcturus Therapeutics, Inc. |
Nucleic acids and methods of treatment for cystic fibrosis
|
WO2021159130A2
(en)
|
2020-05-15 |
2021-08-12 |
Modernatx, Inc. |
Coronavirus rna vaccines and methods of use
|
WO2021231901A1
(en)
|
2020-05-15 |
2021-11-18 |
Translate Bio, Inc. |
Lipid nanoparticle formulations for mrna delivery
|